NCT01808599 2026-01-15
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT00738374 2017-08-15
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
Hoffmann-La Roche
Phase 2 Completed
NCT01868893 2017-04-17
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Genentech, Inc.
Phase 2 Completed
NCT00532129 2016-04-06
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
Hoffmann-La Roche
Phase 2 Completed
NCT01563055 2015-08-10
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT01109264 2013-08-23
Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT00025064 2013-08-07
Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00151736 2012-06-11
Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Terminated
NCT00285389 2009-02-12
Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years
French Innovative Leukemia Organisation
Phase 2 Completed